NHS saves record £300 million by switching to cheaper arthritis drug The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service's most costly drug.
The saving - the biggest in NHS history from a single drug negotiation - could pay for 11,700 more community nurses or 19,800 more breast cancer treatments for patients.
The deal has come about through the introduction of "biosimilar" versions of adalimumab, which is prescribed to more than 46,000 patients for hospital-treated, serious conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. The Telegraph
See Also:
The saving - the biggest in NHS history from a single drug negotiation - could pay for 11,700 more community nurses or 19,800 more breast cancer treatments for patients.
The deal has come about through the introduction of "biosimilar" versions of adalimumab, which is prescribed to more than 46,000 patients for hospital-treated, serious conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. The Telegraph
See Also:
- NHS set to save record £300 million on the NHS’s highest drug spend NHS England
- NHS replaces highest-spend drug with £300m cheaper alternative The Guardian
- NHS ditches its 'most expensive drug' which is used by 46,000 arthritis sufferers in bid to save £300million
No comments:
Post a Comment